BACKGROUND: We investigated whether combination therapy with a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus who were at high risk for cardiovascular disease. METHODS: We randomly assigned 5518 patients with type 2 diabetes who were being treated withopen-label simvastatin to receive either masked fenofibrate or placebo. The primary outcome was the first occurrence of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. The mean follow-up was 4.7 years. RESULTS: The annual rate of the primary outcome was 2.2% in the fenofibrate group and 2.4% in the placebo group (hazard ratio in the fenofibrate group, 0.92; 95% confidence interval [CI], 0.79 to 1.08; P=0.32). There were also no significant differences between the two study groups with respect to any secondary outcome. Annual rates of death were 1.5% in the fenofibrate group and 1.6% in the placebo group (hazard ratio, 0.91; 95% CI, 0.75 to 1.10; P=0.33). Prespecified subgroup analyses suggested heterogeneity in treatment effect according to sex, with a benefit for men and possible harm for women (P=0.01 for interaction), and a possible interaction according to lipid subgroup, with a possible benefit for patients with both a high baseline triglyceride level and a low baseline level of high-density lipoprotein cholesterol (P=0.057 for interaction). CONCLUSIONS: The combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke, as compared with simvastatin alone. These results do not support the routine use of combination therapy with fenofibrate and simvastatin to reduce cardiovascular risk in the majority of high-risk patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00000620.) 2010 Massachusetts Medical Society
RCT Entities:
BACKGROUND: We investigated whether combination therapy with a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus who were at high risk for cardiovascular disease. METHODS: We randomly assigned 5518 patients with type 2 diabetes who were being treated with open-label simvastatin to receive either masked fenofibrate or placebo. The primary outcome was the first occurrence of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. The mean follow-up was 4.7 years. RESULTS: The annual rate of the primary outcome was 2.2% in the fenofibrate group and 2.4% in the placebo group (hazard ratio in the fenofibrate group, 0.92; 95% confidence interval [CI], 0.79 to 1.08; P=0.32). There were also no significant differences between the two study groups with respect to any secondary outcome. Annual rates of death were 1.5% in the fenofibrate group and 1.6% in the placebo group (hazard ratio, 0.91; 95% CI, 0.75 to 1.10; P=0.33). Prespecified subgroup analyses suggested heterogeneity in treatment effect according to sex, with a benefit for men and possible harm for women (P=0.01 for interaction), and a possible interaction according to lipid subgroup, with a possible benefit for patients with both a high baseline triglyceride level and a low baseline level of high-density lipoprotein cholesterol (P=0.057 for interaction). CONCLUSIONS: The combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke, as compared with simvastatin alone. These results do not support the routine use of combination therapy with fenofibrate and simvastatin to reduce cardiovascular risk in the majority of high-risk patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00000620.) 2010 Massachusetts Medical Society
Authors: James Shepherd; Philip Barter; Rafael Carmena; Prakash Deedwania; Jean-Charles Fruchart; Steven Haffner; Judith Hsia; Andrei Breazna; John LaRosa; Scott Grundy; David Waters Journal: Diabetes Care Date: 2006-06 Impact factor: 19.112
Authors: A Keech; R J Simes; P Barter; J Best; R Scott; M R Taskinen; P Forder; A Pillai; T Davis; P Glasziou; P Drury; Y A Kesäniemi; D Sullivan; D Hunt; P Colman; M d'Emden; M Whiting; C Ehnholm; M Laakso Journal: Lancet Date: 2005-11-26 Impact factor: 79.321
Authors: Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: David C Goff; Hertzel C Gerstein; Henry N Ginsberg; William C Cushman; Karen L Margolis; Robert P Byington; John B Buse; Saul Genuth; Jeffrey L Probstfield; Denise G Simons-Morton Journal: Am J Cardiol Date: 2007-04-12 Impact factor: 2.778
Authors: John B Buse; J Thomas Bigger; Robert P Byington; Lawton S Cooper; William C Cushman; William T Friedewald; Saul Genuth; Hertzel C Gerstein; Henry N Ginsberg; David C Goff; Richard H Grimm; Karen L Margolis; Jeffrey L Probstfield; Denise G Simons-Morton; Mark D Sullivan Journal: Am J Cardiol Date: 2007-04-16 Impact factor: 2.778
Authors: Henry N Ginsberg; Denise E Bonds; Laura C Lovato; John R Crouse; Marshall B Elam; Peter E Linz; Patrick J O'connor; Lawrence A Leiter; Daniel Weiss; Edward Lipkin; Jerome L Fleg Journal: Am J Cardiol Date: 2007-04-12 Impact factor: 2.778
Authors: William C Cushman; Richard H Grimm; Jeffrey A Cutler; Gregory W Evans; Sarah Capes; Marshall A Corson; Laurie S Sadler; Michael H Alderman; Kevin Peterson; Alain Bertoni; Jan N Basile Journal: Am J Cardiol Date: 2007-04-16 Impact factor: 2.778
Authors: Russell Scott; Richard O'Brien; Greg Fulcher; Chris Pardy; Michael D'Emden; Dana Tse; Marja-Riitta Taskinen; Christian Ehnholm; Anthony Keech Journal: Diabetes Care Date: 2008-11-04 Impact factor: 19.112
Authors: Mariana C Calle; Sonia Vega-López; Sofia Segura-Pérez; Jeff S Volek; Rafael Pérez-Escamilla; Maria Luz Fernandez Journal: J Diabetes Metab Date: 2010-11-10
Authors: H Carlijne Hassing; Hans Mooij; Shuling Guo; Brett P Monia; Keyang Chen; Wim Kulik; Geesje M Dallinga-Thie; Max Nieuwdorp; Erik S G Stroes; Kevin Jon Williams Journal: Hepatology Date: 2012-06 Impact factor: 17.425